[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uterine-fibroids\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uterine-fibroids":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,42,68,104,132,154,181,204,233,264],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100622013","phase-3-to-evaluate-the-efficacy-and-safety-of-klh-2109-in-patients-with-uterine-fibroids-and-menorrhagia-100622013",false,"NCT07378098","to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia","A Multi-center, Randomized, Double-blind, Active-controlled, Parallel, Phase 3 Study to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia","Inclusion Criteria:\n\n* Individuals diagnosed with uterine fibroids\n\nExclusion Criteria:\n\n* Metrorrhagia or anovulatory bleeding\n* Patients with a history of total hysterectomy or bilateral oophorectomy","FEMALE","19 Years",{"count":19,"type":20},254,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this clinical trial was to determine whether the investigational drug KLH-2109 is effective for treating excessive menstrual bleeding in patients with uterine fibroids. Uterine fibroids are benign tumors that grown in the uterus.\n\nThe primary objectives of this trial were to answer the following questions:\n\n* Does KLH-2109 lower the amount of menstrual bleeding?\n* Does KLH-2109 reduce menstrual bleeding?\n* Is KLH-2109 safe for participants to use?\n\nInvestigators will compare KLH-2109 with a standard of care treatment (control) to determine which treatment is more effective.\n\nParticipants will be required to follow:\n\n* Take either KLH-2109 or the common treatment as a pill\n* Visit the clinic regularly for health checkups and safety tests\n* Keep track of their bleeding and any health changes during the study",[26,27],"Menorrhagia","Uterine Fibroids",[27,26],"RECRUITING","2026-04-27",{"date":32,"type":33},"2026-05-01","ACTUAL",{"date":35,"type":33},"2026-02-03",{"date":37,"type":20},"2028-09-03",{"name":39,"class":40},"JW Pharmaceutical","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100632383","single-channel-fibroid-morcellation-system-used-in-clinical-research-on-laparoscopic-myomectomy-100632383","NCT07512973","Single-channel Fibroid Morcellation System Used in Clinical Research on Laparoscopic Myomectomy","Single-channel Fibroid Morcellation System Used in Clinical Research on Laparoscopic","Inclusion Criteria:\n\n1. Patients with uterine fibroids who meet the surgical criteria.\n2. Aged 18 and above but below 45, those who firmly request to retain the uterus.\n3. Patients planning to undergo laparoscopic removal of uterine fibroids.\n4. Those who understand the purpose, procedures, possible risks of this trial, voluntarily participate in this study, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients whose overall condition cannot tolerate laparoscopic surgery.\n2. Patients who require surgeries other than laparoscopic fibroid removal surgery (excluding pelvic adhesion release, excision of mesosalpinx cysts less than 2cm, and excision\u002Felectrocoagulation of superficial intraperitoneal lesions).\n3. Considering the possibility of malignant transformation of uterine fibroids preoperatively.\n4. Preoperative diagnosis is unclear and needs to be differentiated from ovarian tumors.\n5. History of previous lower abdominal surgery or severe pelvic or abdominal adhesions.\n6. Presence of untreated infectious sexual diseases, including but not limited to vaginitis, cervicitis, and pelvic inflammatory disease.","18 Years","45 Years",{"count":52,"type":20},78,[54],"NA","This prospective, single-center, randomized, single-blind controlled trial aims to evaluate the efficacy and safety of a novel single-channel retrieval bag compared to a widely used dual-channel retrieval bag in laparoscopic myomectomy. A total of 78 patients aged 18 to 45 years with uterine fibroids (diameter ≥ 4 cm and requiring preservation of the uterus) will be randomly assigned to the experimental group and the control group in a 1:1 ratio. The experimental group will use the single-channel system (an upgraded high-transparency large-capacity retrieval bag + fragmentation device with a fibroid limiter), while the control group will utilize a standard dual-channel bag + fragmentation device with a fibroid limiter. The primary outcome measure will be the total surgical time. Secondary outcome measures will include the success rate of placement, intraoperative leakage rate, surgeon's learning curve, and intraoperative\u002Fpostoperative complications. Patients will be followed up at 3 months, 6 months, 12 months, and 24 months to assess recurrence and the risk of fibroid dissemination. Preliminary data (n = 22) indicate that the single-channel myomectomy fragmentation system significantly reduced total sampling time (15.4 minutes vs. 36.7 minutes, p = 0.005) while demonstrating comparable safety. This study utilizes the same electric fragmentation device for both the experimental and control groups, with the experimental group employing a further upgraded single-channel retrieval bag to verify the advantages of the novel single-channel retrieval bag in simplifying surgical procedures, improving efficiency, and providing a smoother learning curve, thereby offering evidence for its clinical promotion and patent conversion, particularly suitable for primary care hospitals.",[27],"NOT_YET_RECRUITING","2026-04-03",{"date":60,"type":33},"2026-04-06",{"date":62,"type":20},"2026-05",{"date":64,"type":20},"2029-05",{"name":66,"class":67},"First People's Hospital of Hangzhou","OTHER",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":41},"100631514","transmucosal-uterosacral-electrical-stimulation-for-pelvic-pain-relief-100631514","NCT07501676","Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain Relief","TUNES","Inclusion Criteria:\n\n* Female, 28-52 years of age\n* Scheduled to undergo uterine fibroid embolization (UFE) at Weill Cornell Medicine\n* Able to provide informed consent\n* Willing to comply with all study procedures and follow-up\n* Fluent in English (for completion of study assessments)\n\nExclusion Criteria:\n\n* Known or suspected pregnancy\n* Active pelvic infection\n* History of pelvic inflammatory disease within the past 6 months\n* Implanted electrical device (e.g., pacemaker, neurostimulator)\n* Current use of opioid pain medication prior to procedure\n* History of chronic pelvic pain not related to fibroids\n* Known allergy or sensitivity to medical-grade silicone\n* Participation in another interventional study within 30 days","28 Years","52 Years",{"count":78,"type":20},60,[54],"This study will test whether gentle electrical stimulation to nerves near the uterus can reduce pelvic pain after uterine fibroid embolization. The investigators hypothesize that participants receiving active TUNES stimulation will experience lower pain levels and improved early recovery compared to those receiving sham stimulation or standard care.",[82,83,27,84,85],"Postoperative Pain After Uterine Fibroid Embolization","Uterine Fibroids (UF)","Pelvic Pain","Pain Management",[87,73,88,89,90,91,92,93,94],"Transmucosal Uterosacral Electrical Stimulation","Uterine Fibroid Embolization","UFE","Post-UFE Pain","Electrical Stimulation Therapy","Pelvic Pain Relief","Noninvasive Neuromodulation","Weill Cornell Medicine","2026-03-24",{"date":97,"type":33},"2026-03-30",{"date":99,"type":20},"2026-04-01",{"date":101,"type":20},"2026-09-30",{"name":103,"class":67},"Weill Medical College of Cornell University",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100473705","vitamin-d-epigallocatechin-gallate-d-chiro-inositol-and-vitamin-b6-in-uterine-fibroid-100473705","NCT05448365","Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid","The Use of Vitamin D in Combination With Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in the Treatment of Women With Uterine Fibroid","Inclusion Criteria:\n\n1. uterine fibroid with diameter greater than or equal to 4cm or multiple fibroids\n2. eligible for surgery\n3. symptoms like menometrorrhagia or pelvic pain\n\nExclusion Criteria:\n\n1. BMI\\>30\n2. currently pregnant or breastfeeding\n3. diabetic\n4. suspect of malignancy\n5. diagnosis of cancer","30 Years","40 Years",{"count":78,"type":20},[54],"The study will evaluate the impact on uterine fibroids' volume of a combination of natural molecules including Epigallocatechin gallate, Vitamin D, D-chiro-inositol and Vitamin B6.\n\nThe patients will be evaluated at baseline and after three months of treatment with placebo or product.",[27,117,118,119,120,121],"D-chiro-inositol","Inositol","Epigallocatechin Gallate","Vitamin D","Vitamin B6","2026-02-10",{"date":124,"type":33},"2026-02-12",{"date":126,"type":33},"2022-07-01",{"date":128,"type":20},"2026-07-01",{"name":130,"class":40},"Lo.Li.Pharma s.r.l",2,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":41},"100567696","phase-3-efficacy--safety-study-of-relugolix-in-women-with-heavy-menstrual-bleeding-associated-with-uterine-fibroids-100567696","NCT06671548","Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Designed Efficacy and Safety Study to Evaluate Relugolix Tablets in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","Inclusion Criteria:\n\n* Premenopausal female aged 18 or older\n* Diagnosis of uterine fibroids confirmed by transvaginal\u002Frectal ultrasound during the screening period\n* Heavy menstrual bleeding caused by uterine fibroids\n* Breast ultrasound results during the screening period meet the BI-RADS classification of 1 to 3\n* Able to understand and comply with the study procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing\n\nExclusion Criteria:\n\n* History of bilateral oophorectomy, or planned to undergo hysterectomy, bilateral oophorectomy, or other surgical procedures during the study period.\n* Previous treatment with gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists for uterine fibroids has failed.\n* History of or current osteoporosis or other metabolic bone disease.\n* History of malignant tumor within 5 years prior to screening, except for cured skin cancer, basal cell carcinoma, and other localized malignant tumors.\n* History of drug abuse, alcohol abuse, or drug dependence within 2 years prior to screening.\n* Presence of an in situ copper intrauterine device (IUD) or a progestin-containing IUD implant\u002Fsubdermal contraceptive implant during the screening period; subjects who can remove the IUD\u002Fsubdermal contraceptive implant at least 1 month before enrollment may be allowed to participate.\n* Baseline bone mineral density Z-score of \\\u003C -2.0 at the lumbar spine, total hip, or femoral neck during the screening period.\n* Any other factors that the investigator deems unsuitable for participation in this trial.",{"count":140,"type":20},120,[23],"The goal of this clinical trial is to determine the benefit of relugolix 40 milligrams (mg) once a day compared with placebo in heavy menstrual bleeding associated with uterine fibroids. The main question\\[s\\] it aims to answer are:\n\n* the benefit of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids\n* the safety of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids",[144,27],"Heavy Menstrual Bleeding","2026-01-29",{"date":147,"type":33},"2026-02-02",{"date":149,"type":33},"2024-01-15",{"date":151,"type":20},"2027-01-07",{"name":153,"class":40},"Qilu Pharmaceutical Co., Ltd.",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":164,"studyType":165,"phases":4,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":4},"100606590","prospective-validation-study-of-a-uterine-fibroid-related-infertility-prediction-model-100606590","NCT07177534","Prospective Validation Study of a Uterine Fibroid-Related Infertility Prediction Model","Inclusion Criteria:\n\n* Women aged 20-50 years with recent desires for conception. Diagnosed with uterine fibroids via ultrasound or pathology. Complete clinical records available. Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Active severe infectious or rheumatologic autoimmune diseases. History of malignant tumors. Incomplete clinical records. Unable to contact via phone or refusal to participate in follow-up.","20 Years","50 Years",{"count":163,"type":20},7084,"5 Years","OBSERVATIONAL","Female fertility may be affected by uterine fibroids, although this association has not been elucidated. Our retrospective study has already constructed a predictive model for infertility risk in patients with uterine fibroids using machine learning. We will now validate and optimize this model through a prospective study",[27,168],"Female Infertility",[170,168,171],"Uterine fibroids","Pregnancy rate","2025-09-16",{"date":174,"type":33},"2025-09-17",{"date":176,"type":20},"2025-09-30",{"date":178,"type":20},"2031-09-30",{"name":180,"class":67},"Tongji Hospital",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":50,"enrollmentInfo":188,"targetDuration":4,"studyType":21,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":41},"100598991","an-open-label-study-to-evaluate-the-effect-of-elix-cycle-balance--elix-daily-harmony-on-fibroid-related-symptoms-100598991","NCT07078682","An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms","An Open-Label, Single-Group Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms","Inclusion Criteria:\n\n* Be female.\n* Be aged 20-45.\n* BMI 18.5 - 24.9 kg\u002Fm2\n* Self-reported prior diagnosis of uterine fibroids.\n* Anyone who is generally healthy - does not live with any uncontrolled chronic disease.\n* Self-reported moderate to severe discomfort during menstruation, related to pelvic cramps, bloating, mood swings, or fatigue.\n* Self-reported menstrual cramps during their cycle, for the past six months minimum.\n* If taking hormonal birth control, has been doing so consistently for at least three months, and experiences a menstrual cycle with a period.\n* If taking other oral over-the-counter supplements or herbal remedies, has been consistently taking these for at least three months prior to starting the study, and is willing to maintain this routine for the study duration.\n* Willing to refrain from introducing any products or any new forms of medication or supplements for the study duration.\n* Willing to refrain from any other dietary supplements or herbal remedies targeting the menstrual cycle during the study period.\n* Willing to refrain from any new vaccines during the 6 month period.\n* Follows a stable, consistent exercise regimen and are willing, for the duration of the study, to not decrease or increase the amount of exercise in their regimen.\n* Agrees to refrain from any lifestyle changes that may affect their menstrual cycle for the duration of the study (for example, getting on or off hormonal birth control, reducing the amount of exercise).\n* If using any other interventions, such as massage, chiropractic medicine, or acupuncture, agrees not to increase or decrease the number of these other interventions during the study period.\n* Resides in the United States.\n\nExclusion Criteria:\n\n* Does not experience a regular menstrual cycle (21-35 days).\n* Does not experience menstrual cramping.\n* Follows an extreme diet intervention such as dry fasts, water fasts, or ketogenic diets.\n* Anyone who has experienced significant weight loss in the past three months prior to study participation.\n* Unwilling to stop the use of any medication or herbal remedies\u002Fsupplements that can affect the menstrual cycle.\n* Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.\n* Anyone with known severe allergic reactions.\n* Anyone with any allergies or sensitivities to any of the study product ingredients.\n* Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).\n* Anyone unwilling to follow the study protocol.\n* Has stopped, started, or changed hormonal birth control in the past three months.\n* Previous users of Elix Cycle Balance.\n* Anyone who is currently a smoker or has been a smoker in the past 3 months.\n* Anyone who has been diagnosed with the following conditions: PCOS, Endometriosis, PMDD, Adenomyosis, Hashimoto's thyroiditis, Grave's disease (and any other thyroid disorders), hyperprolactinemia, Cushing's disease, congenital adrenal hyperplasia, anorexia, bulimia, orthorexia, binge eating, any other eating disorder.\n* History of endocrine disorders such as thyroid disorder, Type 1 or 2 diabetes, or other.\n* History of hypertension, hyperlipidemia, or previous venous embolism.\n* Overweight\u002Fobesity (BMI \\> 25 kg\u002Fm2).\n* Women with other causes of chronic pelvic pain, including infectious disease, gastrointestinal, psychological disorders, fibromyalgia, and chronic fatigue syndrome.\n* Hysterectomy, myomectomy, or bilateral salpingo-oophorectomy or other gynecological medical or surgical treatment in the last 6 months.\n* History of an abnormal pap smear.\n* History of neoplasia of gynecological origin and\u002For existence of uterine malformations.\n* Chronic urinary tract infections or diagnosed functional gastrointestinal conditions like IBS, IBD, Crohn's disease, or ulcerative colitis.\n* Currently partaking in another research study or will be partaking in any other research study for the next 24 weeks, or at any point during this study's duration.\n* Consume more than 5 alcoholic drinks per week\n* Had a vaccine in the last 3 months",{"count":189,"type":20},42,[54],"This is a 24-week, single-arm, open-label, virtual study evaluating the effects of Elix Cycle Balance and Elix Daily Harmony on uterine fibroid-related symptoms and quality of life in 42 participants. Participants will self-administer the investigational herbal supplements daily and complete validated questionnaires at scheduled timepoints to assess symptom severity and quality of life.",[27,193,194],"Leiomyoma","Menstrual Pain","2025-09-07",{"date":197,"type":33},"2025-09-12",{"date":199,"type":33},"2025-08-01",{"date":201,"type":20},"2026-01",{"name":203,"class":40},"Zenchi, Inc.",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":161,"enrollmentInfo":211,"targetDuration":4,"studyType":21,"phases":213,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":140},"100505506","phase-3-a-phase-3b-study-to-evaluate-bone-mineral-density-with-long-term-use-of-relugolix-combination-tablet-in-women-with-uterine-fibroids-or-endometriosis-100505506","NCT05862272","A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis","A Phase 3B, Single-Arm, Open-Label Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids or Moderate to Severe Pain Associated With Endometriosis","Key Inclusion Criteria:\n\n* Is a premenopausal woman, 18 to 50 years of age (inclusive);\n* A diagnosis of uterine fibroids confirmed by imaging or review of medical records and reports heavy menstrual bleeding negatively affecting quality of life. or\n* A diagnosis of endometriosis that is associated with moderate to severe pain.;\n* If at risk of pregnancy is willing to avoid pregnancy for 4 years (the duration of the treatment period) using nonhormonal methods of contraception.\n* Has a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at the allocation visit (or Month 12 if entering from MVT-601-050 \\[NCT04756037; SERENE\\]);\n* In good physical and mental health based on medical, surgical, and gynecological history as well as physical, gynecological, and breast examinations, clinical laboratory test results, and vital sign measurements;\n* Has a body mass index ≥ 18 kg\u002Fm\\^2.\n\nKey Exclusion Criteria:\n\n* Has a weight or body habitus that exceeds the limit of the DXA scanner or has a condition that precludes an adequate DXA measurement at the lumbar spine or proximal femur\n* Has a DXA result demonstrating the following criteria at any anatomic site (lumbar spine, total hip, femoral neck):\n\n  1. For patients entering de novo a Z-score ≤ -1.5 or T-score ≤ -2.0 (if ≥ 40 years of age)\n  2. For patients entering from MVT-601-050 (NCT04756037; SERENE) a 12-month on-treatment DXA demonstrating Z-score ≤ -2.0, T-score ≤ -2.5 (if ≥ 40 years of age), or BMD loss ≥ 8% compared with pre-treatment baseline;\n* Screening 25-OH vitamin D level \\\u003C 12 ng\u002FmL (patients with 25-OH vitamin D deficiency with levels ≥ 12 to \\\u003C 20 ng\u002FmL are permitted if supplementing with vitamin D or if vitamin D supplementation is started in the screening period);\n* Has a history of or currently has Cushing's Syndrome, Rheumatoid Arthritis, metabolic bone disease, uncorrected hyperparathyroidism, Paget's disease of the bone, collagen vascular disease, Marfan's syndrome, Ehlers-Danlos syndrome (if confirmed on genetic testing or meets definitive criteria for hypermobility type), chronic kidney disease (CKD) stage 3 or greater with glomerular filtration rate (GFR) \\\u003C 60 mL\u002Fmin\u002Fm2 using Modification of Diet in Renal Disease (MDRD) method, hyperprolactinemia, known pituitary adenoma, hyperthyroidism, anorexia nervosa, bulimia (within the last year), abnormal bone mineral metabolism (eg, hypophosphatemia). Patients whose hyperparathyroidism or hyperthyroidism has been successfully treated or whose hyperprolactinemia has been successfully treated are allowed;\n* History of low trauma (fragility) fracture.\n* Past history of use or current use of medication used to treat bone loss other than calcium and vitamin D preparations;\n* Prior use of depot-medroxyprogesterone acetate for a treatment period \\> 2 years (if treatment occurred within the past 5 years) or prior use of GnRH agonist or antagonist for \\> 12 months total (unless directly entering from MVT-601-050 \\[NCT04756037; SERENE\\]);\n* Malabsorptive disease (including, but not limited to, inflammatory bowel disease and gastric bypass surgery);\n* Current breast cancer, history of breast cancer or other hormone-sensitive malignancy, at increased risk for hormone-sensitive malignancy, or taking an aromatase inhibitor for breast cancer treatment or prevention\n* History of organ transplantation or history of bone marrow\n* BIRADS ≥ 3 Mammogram at entry (or within the past 6 months).\n* Has a known human immunodeficiency virus (HIV) infection or at high risk of contracting HIV\n* Has a current psychiatric disorder that would, in the investigator or medical monitor's opinion, impair the ability of the patient to participate in the study or would impair interpretation of their data.\n* Is currently using a hormonal intrauterine device or contraceptive implant, hormonal contraceptive, or other prohibited medication and is unwilling to discontinue this hormonal contraception",{"count":212,"type":20},1000,[23],"The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.",[27,216],"Endometriosis",[218,219,216,220,221,222,223],"Uterine Leiomyomas","Fibroids","Bone Mineral Density","Relugolix","Estradiol","Norethindrone acetate","2025-07-31",{"date":226,"type":33},"2025-08-06",{"date":228,"type":33},"2023-08-14",{"date":230,"type":20},"2030-09",{"name":232,"class":40},"Sumitomo Pharma Switzerland GmbH",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":242,"briefSummary":243,"conditions":244,"keywords":251,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":41},"100579755","a-clinical-study-on-the-feasibility-and-safety-of-abdominal-endoscopic-single-port-surgery-system-to-assist-gynecological-day-surgery-100579755","NCT06828419","A Clinical Study on the Feasibility and Safety of Abdominal Endoscopic Single-port Surgery System to Assist Gynecological Day Surgery","Inclusion Criteria:\n\n1. Women aged 18 to 75 years old, with a body mass index (BMI) of no more than 32 kg\u002Fm2;\n2. Conscious, no history of mental illness, accompanied by an adult during the perioperative period;\n3. Educate the subjects, who are willing to undergo day surgery, understand and accept the surgical method and anesthesia method;\n4. Subjects and families understand perioperative care and are willing and able to complete post-discharge care;\n5. Elective surgery, no serious complications affecting the operation and prognosis, aCCI age adjusted comorbidity index 0 points;\n6. According to the adhesion risk scoring system of European Anti-Adhesions in Gynaecology Expert Panel (ANGEL), the adhesion risk was divided into three levels: high, medium and low. Subjects with low risk (0 to 12 points) and abdominal wall scarring and pelvic cavity B-ultrasonography do not indicate obvious pelvic cavity adhesion wiil be included.\n\nExclusion Criteria:\n\n1. Moderate and high-risk patients will be excluded based on ANGEL adhesion risk scoring system;\n2. Subjects with hemorrhagic rupture of ectopic pregnancy and unstable vital signs;\n3. Genital tract infection or in the acute phase of systemic infection;\n4. Subjects on long-term anticoagulant therapy or with coagulation dysfunction;\n5. Subjects have severe heart and lung disease, liver and kidney dysfunction, and cannot tolerate anesthesia;\n6. A history of abdominal or diaphragmatic hernia, abnormal umbilical cord development, or umbilical surgery;\n7. Not willing to undergo endoscopic surgery;\n8. Participated in other drug and device clinical trials within 3 months before surgery.","75 Years",{"count":241,"type":20},63,[54],"In this study, a prospective study is used to select patients who will undergo intra-abdominal endoscopic single-port surgery system for benign gynecological diseases from February 2025 to December 2026 in the Second Affiliated Hospital of Wenzhou Medical University, including hysterectomy, myomectomy, ovarian cyst removal and adnexectomy. The study will perform statistical analysis to evaluate the feasibility and the main factors affecting the safety of intra-abdominal endoscopic single-port surgery system(SR-ENS-600) used in gynecological day surgery.",[245,27,246,247,248,249,250],"Adenopathy","Ovarian Cysts","Adnexal Mass","Ovarian Diseases","Adnexal Cyst","Adnexal Diseases",[252,253,254],"robotic-assisted laparoscopic single-site surgery (R-LESS)","single-port robot system (SPRS)","day surgery","2025-03-27",{"date":257,"type":33},"2025-04-03",{"date":259,"type":20},"2025-04-10",{"date":261,"type":20},"2026-12-31",{"name":263,"class":67},"Second Affiliated Hospital of Wenzhou Medical University",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":270,"sex":16,"minAge":160,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":165,"phases":4,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":4},"100520326","study-on-vaginal-microecology-and-cervical-local-immune-function-in-patients-with-uterine-fibroids-of-childbearing-age-100520326","NCT06055114","Study on Vaginal Microecology and Cervical Local Immune Function in Patients With Uterine Fibroids of Childbearing Age","Inclusion Criteria:\n\nStudy group inclusion criteria:\n\n* Age 20-49 years old\n* Premenopausal\n* Clinical diagnosis of uterine myoma\n* Cervical liquid-based cytology and human papillomavirus typing test are negative\n\nHealthy control group:\n\n* Age 20-49 years old\n* Premenopausal\n* Uterine B-ultrasonography is normal\n* Cervical liquid-based cytology and human papillomavirus typing test are negative\n* No vaginal infection\n\nExclusion Criteria:\n\nExclusion criteria of the study group:\n\n* Used antibiotics, hormones, immunosuppressants and regulators within 1 month\n* Sex, vaginal irrigation or applied medicine 3 days before the vaginal discharge sampling\n* Pregnant, lactating or menstruating women\n* Uterus and uterine adnexa have other lesions\n\nExclusion criteria of healthy control group:\n\n* Used antibiotics, hormones, immunosuppressants and regulators within 1 month\n* Sex, vaginal irrigation or applied medicine 3 days before the vaginal discharge sampling\n* Pregnant, lactating or menstruating women",true,"49 Years",{"count":273,"type":20},300,"The study participants are patients with uterine fibroids and healthy physical examination subjects from the First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital). The main purpose of this study is to analyze the correlation between uterine fibroids and vaginal microecology and cervical local immune function in patients of childbearing age.",[27],[277,278,279,280],"uterine fibroids","vaginal microecology","cervical local immune function","childbearing age","2023-09-23",{"date":283,"type":33},"2023-09-26",{"date":285,"type":20},"2023-10-09",{"date":287,"type":20},"2026-10-09",{"name":289,"class":67},"Lin Yuan"]